Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Klarna, the specialty lending and online payments provider, has halted its planned initial public offering, the latest IPO casualty in the wake of the Trump administration’s sweeping tariff ...

As per Inc42 data, 20 startups are in various stages of undertaking their IPO preparations at the outset of 2025 Key factors that are likely to contribute to the public listing mania in 2025 are ...

If your aggregate position is larger than Tier 1, your margin requirement will not be reduced by non-guaranteed stops. Please note: we have tried to ensure that the information here is as accurate as ...

We built our IPO process in partnership with the investment banking community, ensuring that they have the control and information they need to successfully open your IPO. Nasdaq’s best-in-class ...

Rapidly growing companies like CoreWeave can be highly volatile and risky. Before investing in an IPO, check its performance and market reception post-launch. An IPO stock is a stock that has ...